Skip to main content

Table 3 Landmark clinical trials in the development of VEGF inhibitors

From: Clinical development of targeted and immune based anti-cancer therapies

Drug Name Clinical Trial ID Trial Name Population Comparator Year Sponsor Phase N Median OS (months) Median PFS (months)
VEGF inhibitors
 Sorafenib (Nexavar®)
  Sorafenib (400 mg BD) NCT00073307 TARGET Metastatic RCC Placebo 2003–2006 Bayer III 903 17.8 vs 15.2 5.5 vs 2.8
  Sorafenib (400 mg BD) NCT00984282   Thyroid cancer Placebo 2009–2012 Bayer III 417 52.7 vs 54.8% 10.8 vs 5.8
 Bevacizumab (Avastin®)
  Bevacizumab (10 mg/kg/2w) NCT00281697 RIBBON 2 Metastatic Breast Cancer Placebo 2006–2009 Genentech III 684 18.6 vs 17.8 7.2 vs 5.1
  Bevacizumab (5 mg/kg/w) NCT00528567 BEATRICE Breast cancer (triple negative) Standard adjuvant chemotherapy 2007–2012 Hoffmann-La Roche III 2591 NR NR
  Bevacizumab (10 mg/kg/2w) NCT00028990 E2100 Metastatic breast cancer Paclitaxel 2001–2006 Eastern Cooperative Oncology Group III 722 NR 11.8 vs 5.9
  Bevacizumab (5 mg/kg/w) NCT01169558   Metastatic CRC Combination with Fluoropyrimidine-based Chemotherapy 2006–2009 Hoffmann-La Roche III 162 21.6 11.0
  Bevacizumab (15 mg/kg/3w) NCT01239732   Ovarian cancer Paclitaxel + Carboplatin 2010–2015 Hoffmann-La Roche III 1021 NA 25.5
  Bevacizumab (dose NR) + chemotherapy NCT00565851 GOG-0213 Ovarian, Epithelial, Peritoneal, Fallopian Tube Cancer Chemotherapy 2007–2019 National Cancer Institute III 1038 42.2 vs 37.3 13.8 s 10.4
  Bevacizumab (15 mg/kg/3w) + chemotherapy NCT00434642 OCEANS Ovarian cancer Chemotherapy 2007–2013 Genentech III 484 33.6 vs 32.9 12.4 vs 8.4
  Bevacizumab (10 mg/kg/w) + IFNα2A NCT00738530 AVOREN RCC IFNα2A 2004–2008 Hoffmann-La Roche III 649 23.3 vs 21.3 10.2 vs 5.5
  Bevacizumab (15 mg/kg/3w) + chemotherapy NCT00803062 GOG-240 Cervical cancer Chemotherapy 2008–2017 National Cancer Institute III 452 17.5 vs 14.3 9.6 vs 6.7
  Bevacizumab (10 mg/kg) NCT00345163 BRAIN Glioblastoma Chemotherapy 2006–2007 Genentech II 167 8.7 vs 9.2 50.3 vs 42.6%
  Bevacizumab (10 mg/kg) NCT01351415   NSCLC Chemotherapy 2006–2014 Hoffmann-La Roche III 485 11.9 vs 10.2 5.5 vs 4.0
 Ramucirumab (Cryamza®)
  Ramucirumab (8 mg/kg/2w) NCT00917384 REGARD Metastatic gastric or gastroesophageal junction cancer Placebo 2009–2015 Eli Lilly and Company III 355 2.1 vs 1.3 5.2 vs 3.8
 Aflibercept (EYLEA®)
  Aflibercept (4 mg/kg) + FOLFIRI NCT00561470 VELOUR CRC FOLFIRI 2007–2012 Sanofi III 1226 13.5 vs 12.1 6.9 vs 4.7
  Aflibercept (4 mg/kg) + docetaxel NCT00532155 VITAL Metastatic NSLC Docetaxel 2007–2011 Sanofi III 913 10.1 vs 10.4 5.2 vs 4.1
  Aflibercept (4 mg/kg) + gemcitabine NCT00574275 VANILLA Metastatic pancreatic cancer Gemcitabine 2007–2010 Sanofi III 546 7.8 vs 6.5 3.7 vs 3.7